APL-101 is being evaluated in a phase I/II study in patients with NSCLC with c-Met dysregulation in advanced solid tumors, specifically in the C2 cohort in patients with EGFR-positive NSCLC who have MET amplification as acquired resistance to first-line EGFR inhibitors (Apollomics, NCT03175224). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.